Searching for treatment options for a KRAS-mutated cancer? Massive Bio can assist with our free clinical trial matching service, providing access to innovative therapies for adults with KRAS-driven solid tumors.
Built on years of collaborative success
160k Patients
19k+ Trials
400+ Partners
45+ Companies
17 Countries
Meet Jose, myelofibrosis patient, who shares how his cancer diagnosis changed his life and the challenges he faced in finding the right treatment..
Jose Luke Komacho, Myelofibrosis Cancer
Daniel chose hope. In this deeply personal video, he shares his ongoing journey with honesty and strength.
Daniel White, Stage 4 Metastatic Lung Cancer
From uncertainty to breakthrough, Brain's journey highlights the life-saving potential of clinical trials.
Brian O'Sullivan, Mantle Cell Lymphoma
Our AI-driven engine never stops until you succeed.
A cancer diagnosis can be overwhelming, especially when you learn your tumor carries a specific genetic mutation like KRAS. In recent years, major scientific breakthroughs have led to new targeted therapies specifically designed to address KRAS mutations.When standard treatments stop working, or when you receive a new diagnosis, you may benefit from clinical trials.They may give access to new therapies that target KRAS mutations directly.
KRAS mutations are among the most common genetic alterations in solid tumors. According to National Cancer Institute (NCI/NIH) KRAS mutations are frequently seen in:Pancreatic cancerNon-small cell lung cancer (NSCLC)Colorectal cancerGastric (stomach) cancerUterine (endometrial) cancerOvarian cancerUrothelial (bladder) cancerTesticular cancerNew therapies, including KRAS inhibitors, combination targeted treatments, and immunotherapy-based strategies, are transforming treatment options for patients with KRAS-mutated tumors.If you or your loved one has a KRAS mutation, our advanced artificial intelligence (AI) platform can identify clinical trials specifically designed for your tumor’s genetic profile.Once you submit your information, our oncology experts will review your case and contact you to discuss next steps.
Precision Medicine: KRAS mutations are specific genetic changes in cancer cells. Clinical trials use precision medicine to target these mutations directly, aiming to block the signals that allow cancer cells to grow and spread.Access to Novel KRAS-Targeted Therapies: Many KRAS-targeted drugs and combination regimens are available only through clinical trials. These treatments may provide options when standard chemotherapy or immunotherapy has stopped working.Combination Strategies: Researchers are studying combinations of KRAS inhibitors with chemotherapy, immunotherapy, and other targeted therapies to improve response rates and overcome resistance.Contributing to Scientific Progress: Participation in clinical trials helps advance research and improve future treatment standards for KRAS-driven cancers.
Massive Bio provides:Clinical Trial Matching: We specialize in matching patients with KRAS-mutated solid tumors to appropriate clinical trials worldwide.Access to Experts: Our platform connects patients with oncologists and principal investigators experienced in KRAS-targeted therapies.Navigating Complexity: Understanding molecular reports, eligibility criteria, and enrollment processes can be overwhelming. We guide you every step of the way, from genetic report review to trial enrollment. Our service is free for patients.
Solid tumors refer to cancers that develop in an organ when cells begin growing and dividing uncontrollably due to genetic changes, such as mutations in genes like KRAS. Unlike blood cancers, which affect the bloodstream or bone marrow, these cancers form in organs and tissues.Today, cancer care goes beyond identifying where the cancer started. Doctors also study the tumor’s molecular profile — the specific genetic mutations driving its growth. This information helps guide treatment decisions and may determine whether a patient qualifies for targeted therapies or clinical trials designed specifically for that mutation.The most common KRAS mutation positive solid tumors include:Pancreatic CancerPancreatic cancer most commonly arises from the ducts of the pancreas (pancreatic ductal adenocarcinoma). It is often diagnosed at an advanced stage because symptoms may be subtle early on. Common symptoms include abdominal pain, weight loss, and jaundice.KRAS mutations are present in more than 60% of pancreatic adenocarcinomas, making it one of the most KRAS-driven cancers.Because KRAS plays such a central role in pancreatic cancer biology, clinical trials targeting KRAS pathways are especially relevant in this disease.Colorectal CancerColorectal cancer develops in the colon or rectum and is one of the most common cancers worldwide. It often begins as a benign polyp that gradually becomes cancerous over time.KRAS mutations are identified in approximately 35–40% of colorectal cancers. KRAS status plays a critical role in determining whether certain targeted therapies (like EGFR inhibitors) will be effective.Non-Small Cell Lung Cancer (NSCLC)Non-small cell lung cancer is the most common type of lung cancer. Adenocarcinoma is the most frequent subtype, particularly among non-smokers and former smokers.KRAS mutated lung cancer occur in about 30% of lung adenocarcinomas (KRAS mutation in NSCLC). Recent advances in KRAS-targeted therapies (particularly for specific KRAS variants) have significantly expanded treatment options in this cancer type.Uterine (Endometrial) CancerEndometrial cancer develops in the lining of the uterus and is the most common gynecologic cancer in developed countries. It frequently presents with abnormal uterine bleeding.KRAS mutations occur in approximately 10–20% of endometrial cancers, depending on subtype.Molecular profiling is increasingly used to guide treatment decisions in advanced or recurrent disease.Gastric (Stomach) CancerGastric cancer forms in the lining of the stomach and may present with symptoms such as indigestion, abdominal discomfort, or unexplained weight loss.Researchers also observe KRAS mutations in approximately 10–20% of gastric adenocarcinomas.Although less common than in pancreatic or colorectal cancers, KRAS alterations may influence eligibility for molecularly driven clinical trial.Ovarian CancerOvarian cancer originates in the ovaries or fallopian tubes. It is often diagnosed at an advanced stage because early symptoms may be vague (bloating, abdominal fullness, pelvic discomfort).KRAS alterations are identified in approximately 10% of ovarian cancers overall, with higher prevalence in low-grade serous subtypes.Targeted therapies and clinical trials may be available depending on molecular findings.Urothelial (Bladder) CancerUrothelial cancer typically begins in the lining of the bladder and may cause blood in the urine, urinary frequency, or pelvic pain.KRAS mutations are less frequent, occurring in approximately 8% of cases, but remain clinically relevant in molecular profiling and trial eligibility.Testicular CancerTesticular cancer most often affects younger adult men and may present as a painless lump or swelling. Most cases are highly treatable, especially when detected early. In testicular germ cell tumors, KRAS mutations are found in approximately 15% of cases, and may reach about 20% in certain subtypes (particularly tumors with seminoma components).
Cancer staging helps determine how far the tumor has spread:Stage 1 (Early): Tumor confined to its original organ.Stage 2: Tumor larger but still localized.Stage 3 (Locally Advanced): Spread to nearby lymph nodes or tissues.Stage 4 (Metastatic): Spread to distant organs.Clinical trials may be available at all stages, depending on tumor type and prior treatment history.
Treated Tumor:Refers to a solid tumor that has been treated. Treatment may include surgery, radiation, chemotherapy, or targeted therapy. The goal is to reduce or remove cancer cells. Clinical trials are often available for patients with treated tumors to explore new therapies or monitor long-term outcomes specifically tailored to KRAS-mutated cancers.Untreated Tumor:Refers to a solid tumor that has not yet received any form of medical treatment or intervention and remains in its original state since diagnosis. Clinical trials may be offered to patients with untreated tumors, providing access to innovative treatments as a first-line therapy designed specifically for KRAS-mutated cancers.
Resectable (Surgery-Eligible) Solid Tumor: A resectable solid tumor is one that can be removed through surgery without causing significant harm to surrounding vital structures or organs. Surgery is often considered a primary treatment option for resectable tumors.Unresectable (Not Surgery-Eligible) Solid Tumor: An unresectable solid tumor is one that cannot be safely removed through surgery. This could be due to the tumor’s size, location, or its involvement with critical structures that make surgical removal too risky. In these cases, other treatment options such as chemotherapy, radiation, or targeted therapies are typically explored.We offer clinical trials specifically tailored for patients with unresectable KRAS-mutated solid tumors, providing access to innovative therapies that may not be available through standard treatment options.Our team is dedicated to guiding families through the entire matching process, helping them navigate the complexities of clinical trial enrollment. This support ensures that pediatric patients can explore cutting-edge treatments that could significantly improve their outcomes.
NGS stands for Next-Generation Sequencing, a DNA sequencing technology that reads millions of DNA fragments simultaneously, providing a comprehensive analysis of a tumor’s genetic profile.NGS helps determine a patient’s KRAS mutation status and identify important genetic biomarkers, including specific alterations such as the g12v KRAS mutation, g13d KRAS mutation, and KRAS G12D mutation.These mutations are frequently found in cancers such as KRAS mutation colon cancer, KRAS mutation pancreatic cancer, and lung cancer KRAS mutation cases. For example, the KRAS G12V mutation colon cancer subtype and KRAS G13D mutation colon cancer are common molecular profiles in colorectal cancer, while the KRAS G12V mutation lung cancer and KRAS G12D mutation lung cancer variants are observed in certain non-small cell lung cancer patients.Understanding your KRAS mutation status through comprehensive genomic profiling is critical because certain KRAS alterations may influence prognosis, predict resistance to some therapies, or create opportunities for targeted treatment strategies and clinical trial enrollment. Identifying these mutations early can help personalize treatment decisions and ensure access to innovative investigational therapies designed to target KRAS-driven cancers.NGS testing is considered part of the standard of care for many cancer types. Discuss this with your oncologist to maximize your chances of qualifying for a clinical trial.
The standard treatments typically include surgery, chemotherapy, radiation, immunotherapy, and sometimes stem cell transplants. They aim to eliminate cancer while considering the patient’s well-being. Emerging therapies such as immunotherapy and targeted therapies are the forefront of KRAS-mutated solid tumors.Clinical trials offer hope for better treatments, improved outcomes, and the advancement of medical knowledge. They provide a pathway to potentially more effective and tailored therapies for KRAS-mutated solid tumors.By signing up for our matching program, you take an active role in exploring new options. You also gain access to an innovative therapy that could transform your life.
We offer a quick, easy, and FREE way to find KRAS-mutated solid tumor clinical trials that match your specific condition.Through our advanced Clinical Trial Matching System (CTMS) and oncology expert team, we rapidly identify personalized research opportunities tailored to your tumor’s molecular profile.
What Are Clinical Trials?Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new options. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important option for many cancer patients.We dream of the day when cancer disappears from our lives. Massive Bio is working tirelessly on achieving that goal.
At Massive Bio, every piece of health information you share is protected by industry‑leading safeguards—HIPAA, PIPEDA, GDPR, SOC 2 Type II and PCI‑DSS. Your data stays encrypted and under your control while we match you to the right trial.